The cardiovascular risk of diabetes drugs made by AstraZeneca Plc and Takeda Pharmaceutical Co. is acceptable, though the drugs’ labels should include safety information on heart failure, U.S. advisers said.
Most members of a Food and Drug Administration advisory panel voted Tuesday to recommend the agency add data from trials on the heart effects to the labels of AstraZeneca’s Onglyza and Takeda’s Nesina. They also voted that the drugs’ cardiovascular risk is acceptable.
